New strategies in refractory and recurrent neuroblastoma: translational opportunities to impact patient outcome.
about
Retinoic acid post consolidation therapy for high-risk neuroblastoma patients treated with autologous hematopoietic stem cell transplantationRapid COJEC versus standard induction therapies for high-risk neuroblastomaRapid COJEC versus standard induction therapies for high-risk neuroblastomaRetinoic acid post consolidation therapy for high-risk neuroblastomaPediatric solid tumor genomics and developmental pliancyDual CDK4/CDK6 inhibition induces cell-cycle arrest and senescence in neuroblastoma.Metastatic neuroblastoma cancer stem cells exhibit flexible plasticity and adaptive stemness signaling.Oxaliplatin and Doxorubicin for relapsed or refractory high-risk neuroblastoma.Arsenic Trioxide as a Radiation Sensitizer for 131I-Metaiodobenzylguanidine Therapy: Results of a Phase II Study.Adult neuroblastoma complicated by increased intracranial pressure: a case report and review of the literature.Quantitative phosphoproteomic analysis identifies activation of the RET and IGF-1R/IR signaling pathways in neuroblastoma.Striking dichotomy in outcome of MYCN-amplified neuroblastoma in the contemporary era.Reorganization of metastamiRs in the evolution of metastatic aggressive neuroblastoma cellsImmune modulating effects of cyclophosphamide and treatment with tumor lysate/CpG synergize to eliminate murine neuroblastomaProlonged progression-free survival after consolidating second or later remissions of neuroblastoma with Anti-GD2 immunotherapy and isotretinoin: a prospective Phase II study.RD3 loss dictates high-risk aggressive neuroblastoma and poor clinical outcomes.A dual-specific anti-IGF-1/IGF-2 human monoclonal antibody alone and in combination with temsirolimus for therapy of neuroblastoma.Pre-Clinical Evaluation of rHDL Encapsulated Retinoids for the Treatment of Neuroblastoma.Retinoic acid postconsolidation therapy for high-risk neuroblastoma patients treated with autologous haematopoietic stem cell transplantation.MYCN and HDAC2 cooperate to repress miR-183 signaling in neuroblastomaImproved therapy for neuroblastoma using a combination approach: superior efficacy with vismodegib and topotecanPhase I trial of a bivalent gangliosides vaccine in combination with β-glucan for high-risk neuroblastoma in second or later remission.MYCN-amplified stage 2/3 neuroblastoma: excellent survival in the era of anti-GD2 immunotherapy.A phase I/Ib trial targeting the Pi3k/Akt pathway using perifosine: Long-term progression-free survival of patients with resistant neuroblastoma.
P2860
Q24186451-F0E8D322-8497-49C4-9393-7BAFBDF33CB4Q24187922-448BE08B-9106-4C04-8372-85530FA87A3CQ24197871-A5E77818-9BE3-4648-BCF6-5394C1B16709Q24201495-C8BB3F82-AC44-4E10-A51E-206F010CBC5CQ27023560-F7DE1C87-C95A-4A66-848A-42A68F01920AQ30426051-A58B7F14-2F4A-42AB-AB1E-3AA92BC405FFQ30639268-3C486137-CA91-426B-BD45-7A18CEDF6A63Q33419558-16903E93-6192-4B83-92CE-344EA1122973Q33428982-18960590-A7A5-4A3E-8FA0-280CB0D2EF1EQ34310934-E3308D37-932E-4438-8301-CBBB133CB347Q35070321-FFB37606-57AA-48D1-9C15-8F312BFA8702Q35077703-B6268E1F-AE34-46B2-8B0C-532137673C88Q35684427-21CA0EA9-2752-46B1-8FBF-135EA8C03BF9Q35747826-0E77F534-C16C-48BB-88DB-B7BDB6C94E9EQ35798960-39C13448-C8D7-472E-AA4F-65F66B855640Q36546711-E92483DF-9051-40BB-8713-FD879EEB5FE8Q37162205-777F66B7-608B-429A-9E83-83998A43B27BQ37475635-A8D90E27-4D6D-4E71-A73C-9FE081E12BFDQ38608663-7D3EA5F7-CE80-494F-B7E3-D05EAC23E434Q39158975-D3FB3EFB-2CF1-4613-A3D7-795D326D1115Q39954004-E79754BB-3DB6-4855-AD7C-BC023799EEDCQ41394300-38FE6D00-5E99-4B78-87C2-A3964F5A056AQ47108370-E881F86C-C15F-4A8B-9A77-62485385F9ACQ51483438-01C4B8DC-44A4-4577-85C1-46F8A6C3DB1A
P2860
New strategies in refractory and recurrent neuroblastoma: translational opportunities to impact patient outcome.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
New strategies in refractory a ...... ies to impact patient outcome.
@en
New strategies in refractory a ...... ies to impact patient outcome.
@nl
type
label
New strategies in refractory a ...... ies to impact patient outcome.
@en
New strategies in refractory a ...... ies to impact patient outcome.
@nl
prefLabel
New strategies in refractory a ...... ies to impact patient outcome.
@en
New strategies in refractory a ...... ies to impact patient outcome.
@nl
P2860
P1476
New strategies in refractory a ...... ies to impact patient outcome.
@en
P2093
John M Maris
Kristina A Cole
P2860
P304
P356
10.1158/1078-0432.CCR-11-1409
P407
P577
2012-03-16T00:00:00Z